Thursday, 31 March 2016


State-owned Syndicate Bank in its meeting held on March 31, 2016, has considered and approved the issue of 9.51 crore equity shares of the face value of Rs. 10/- each for cash at Rs. 77.79 determined in accordance with Regulation 76 (1) of SEBI ICDR Regulations aggregating upto Rs. 740.00 Crore (Rupees Seven hundred forty Crore only) on preferential basis to Government of India.

The bank's board directed that the amount of Rs. 740.00 crore, received from Government of India on March 30, 2016, be treated as “Equity Share Application money received - pending allotment” pending all statutory/Regulatory/other approvals.

Also, the board had directed that the Bank may seek permission of RBI and Government of India to treat the equity share application money received as part of Common equity Tier 1 (CET 1) for the purpose of calculation of Capital Adequacy (CRAR). Syndicate Bank ended at Rs. 67.7, up by Rs. 1.65 or 2.5% from its previous closing of Rs. 66.05 on the BSE.

The scrip opened at Rs. 67 and touched a high and low of Rs. 68.5 and Rs. 63.05 respectively. A total of 4990744(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 4645.77 crore. The BSE group 'A' stock of face value Rs. 10 touched a 52 week high of Rs. 118.2 on 29-May-2015 and a 52 week low of Rs. 49.4 on 17-Feb-2016. Last one week high and low of the scrip stood at Rs. 66.45 and Rs. 63.05 respectively. The promoters holding in the company stood at 69.24 % while Institutions and Non-Institutions held 17.73 % and 13.03 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

The bank  has informed BSE that it has allotted 46,39,294 equity shares to General Insurance Corporation of India on a preferential basis on March 30, 2016 at Rs.86.22 per share. The stock ended at Rs. 97.05, up by Rs. 0.55 or 0.57% from its previous closing of Rs. 96.5 on the BSE.

The scrip opened at Rs. 97.5 and touched a high and low of Rs. 99.9 and Rs. 95.3 respectively. A total of 8922660(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 7834.96 crore. The BSE group 'A' stock of face value Rs. 10 touched a 52 week high of Rs. 232.95 on 15-Apr-2015 and a 52 week low of Rs. 80.1 on 17-Feb-2016. Last one week high and low of the scrip stood at Rs. 98.8 and Rs. 93.1 respectively. The promoters holding in the company stood at 70.13 % while Institutions and Non-Institutions held 20.72 % and 9.15 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717


Dishman Pharmaceuticals and Chemicals Ltd has acquired further 50% stake in Schutz Dishman Biotech Ltd., a Joint Venture Indian Company, from the existing JV Partner i.e. SCHUTZ & CO BETEILIGUNGSGESELLSCHAFT MBH, Germany for a consideration of EURO 300,000.Schutz Dishman Biotech is engaged in the business of manufacturing of bulk drugs, drug formulations and performance chemicals in India for export markets. Its plant is USFDA approved and is located in the existing campus of Dishman’s Bavla manufacturing facility.

The said acquisition will help Dishman in backward integration for some of its existing products and for manufacturing other APIs. Presently, company is holding 22.33% stake in Schutz Dishman and after acquisition of further 50% stake, Schutz Dishman will become subsidiary of the company.

Dishman Pharmaceuticals and Chemicals Ltd ended at Rs. 335.85, down by Rs. 2.35 or 0.69% from its previous closing of Rs. 338.2 on the BSE. The scrip opened at Rs. 339 and touched a high and low of Rs. 343.9 and Rs. 334 respectively. A total of 629579(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 2729.27 crore.

The BSE group 'B' stock of face value Rs. 2 touched a 52 week high of Rs. 419.7 on 04-Nov-2015 and a 52 week low of Rs. 126.05 on 03-Jun-2015. Last one week high and low of the scrip stood at Rs. 352.35 and Rs. 332 respectively. The promoters holding in the company stood at 61.4 % while Institutions and Non-Institutions held 23.87 % and 14.73 % respectively. 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

Ahluwalia Contracts (India) Ltd ended at Rs. 295.6, up by Rs. 14.8 or 5.27% from its previous closing of Rs. 280.8 on the BSE. The company bagged orders worth of Rs 115 crore for extension of construction work for Amity University campus Kolkata, worth Rs 49.86 crore for construction of school building for Anandilal & Ganesh Podar Society Mumbai, worth Rs 35 crore for extension of construction work for Bennett University Greater Noida.

The company is currently L1 in project valued around Rs 965 crore and the projects bided under pipeline are Rs 2500 crore, Ahluwalia Contracts (India) said. The total order inflow during the year ending 31 March 2016 stands at Rs 1534.04 crore. The company's unexecuted order book as on date stands at Rs 4025 crore, it added.

The scrip opened at Rs. 284.9 and touched a high and low of Rs. 300 and Rs. 275.7 respectively. A total of 204589(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 1881.01 crore.

The BSE group 'B' stock of face value Rs. 2 touched a 52 week high of Rs. 303 on 06-Jan-2016 and a 52 week low of Rs. 189.2 on 16-Jun-2015. Last one week high and low of the scrip stood at Rs. 284 and Rs. 259 respectively. The promoters holding in the company stood at 62.43 % while Institutions and Non-Institutions held 28.77 % and 8.8 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

SBI subsidiary State Bank of Travancore in its meeting held on March 30, allotted 5,150 Basel III compliant Tier II Bonds in the form of debentures of face value of Rs. 10 lakh each at par aggregating to Rs. 515 crore on a private placement basis.

The bonds tenure period is around ten years bearing 8.45% per annum coupon rate and with call option on March 30, 2021. As of March 31, 2015, SBT has a total business stood at 1.61 trillion (US$25.23 billion), comprising total deposits of 91,077 crore(US$14.29 billion) and gross advances of ₹69,907 crore(US$10.96 billion).

State Bank of Travancore ended at Rs. 388.95, up by Rs. 6.55 or 1.71% from its previous closing of Rs. 382.4 on the BSE. The scrip opened at Rs. 385 and has touched a high and low of Rs. 389.7 and Rs. 377 respectively. So far 17970(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 2719.02 crore.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 487 on 06-May-2015 and a 52 week low of Rs. 360 on 01-Mar-2016. Last one week high and low of the scrip stood at Rs. 386.6 and Rs. 370.5 respectively. The promoters holding in the company stood at 79.09 % while Institutions and Non-Institutions held 2.93 % and 17.98 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

Kotak Mahindra Bank ends marginally lower on BSE. Earlier in the day, around 3.2 million shares changed hands in a block deal. The stock  ended at Rs. 681, down by Rs. 2.6 or 0.38% from its previous closing of Rs. 683.6 on the BSE.

The scrip opened at Rs. 680 and touched a high and low of Rs. 694.9 and Rs. 679.5 respectively. A total of 7562549(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 125364.14 crore.

The BSE group 'A' stock of face value Rs. 5 touched a 52 week high of Rs. 744.45 on 21-Jul-2015 and a 52 week low of Rs. 586.5 on 29-Feb-2016. Last one week high and low of the scrip stood at Rs. 686 and Rs. 660 respectively. The promoters holding in the company stood at 33.74 % while Institutions and Non-Institutions held 39.13 % and 27.14 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

Saint Gobain Sekurit India Ltd closed 10% higher at Rs. 40. Around 11.84 million shares of 13% stake of the company changed hands in a block deal, as per reports. The scrip opened at Rs. 37.05 and touched a high and low of Rs. 42.5 and Rs. 37.05 respectively. A total of 12532999(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 337.56 crore.
The BSE group 'XC' stock of face value Rs. 10 touched a 52 week high of Rs. 54.5 on 03-Aug-2015 and a 52 week low of Rs. 33.15 on 29-Feb-2016. Last one week high and low of the scrip stood at Rs. 38.5 and Rs. 36 respectively.

The promoters holding in the company stood at 75 % while Institutions and Non-Institutions held 0.2 % and 24.8 % respectively.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

Dr. Reddy's Laboratories announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy's will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai's investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy's holds the option for rights to develop and market the agent in India.

In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon  sales targets. Through this agreement, the two companies aim to accelerate development and maximize the value of E7777.

Raghav Chari, Executive Vice President, Proprietary Products Group, Dr. Reddy's Laboratories, said, "The collaboration between DRL and Eisai is a tremendous win-win. E7777 has significant potential as an important component of systemic therapy for CTCL (cutaneous T-cell lymphoma). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers."

Terushige like, Chief Product Creation Officer of Eisai Product Creation Systems, said, "This agreement aligns with Eisai's drive to contribute to patients in our focused field of oncology as quickly as possible. Eisai and Dr. Reddy's will conduct development in their respective territories, and by working to accelerate and maximize contribution to patients, we hope to launch treatments that will fulfill the diverse needs of, and bring about benefits for, patients with cancer and their families." 

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6554125 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717